采用大剂量阿糖胞苷（Ara-C）和重组人粒细胞巨噬细胞集落刺激因子（rHUGM-CSF）治疗预后不良的新诊断急性髓系白血病。
Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF.
作者信息
Estey E H, Kantarjian H M, Beran M, McCredie K B, Keating M J, Deisseroth A, Gutterman J U
机构信息
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
出版信息
Haematol Blood Transfus. 1990;33:732-6. doi: 10.1007/978-3-642-74643-7_134.
We gave 4 days of high-dose Ara-C followed 2 days later by rHUGM-CSF (which continued until the neutrophil count was greater than 1000/microliters) to 12 patients with newly diagnosed AML and a relatively poor prognosis. Six CRs occurred, there were four deaths during induction, and in only one case was there an rHUGM-CSF-associated growth of leukemia. The pattern of hematologic recovery was variable but in some patients rHUGM-CSF seemed to accelerate normal myelopoiesis following chemotherapy. Continued investigation of rHUGM-CSF and chemotherapy in AML is warranted.
我们对12例新诊断的、预后相对较差的急性髓系白血病患者给予4天的大剂量阿糖胞苷，2天后给予重组人粒细胞巨噬细胞集落刺激因子（持续至中性粒细胞计数大于1000/微升）。诱导缓解期间出现6例完全缓解，4例死亡，仅1例出现与重组人粒细胞巨噬细胞集落刺激因子相关的白血病生长。血液学恢复模式各不相同，但在一些患者中，重组人粒细胞巨噬细胞集落刺激因子似乎加速了化疗后的正常骨髓造血。有必要继续研究重组人粒细胞巨噬细胞集落刺激因子和化疗在急性髓系白血病中的应用。
Zotero 插件